Background Intermittent exotropia (IXT) is the most common type of strabismus, overminus lens therapy (OML) is frequently prescribed to treat IXT. Objectives To compare the effectiveness of OML and observation in the treatment of intermittent exotropia. Method An exhaustive search of the literature in Pubmed, EMBASE, Web of Science, and Cochrane Library databases was performed until July 2022. No language restrictions were used. The literature was rigorously screened according to eligibility criteria. Weighted mean differences (WMD) and 95% confidence intervals (CI) were calculated. Results A total of 4 articles with 561 participants were included in this meta-analysis. Our pooled results showed that OML demonstrated superior outcomes compared with observation, with greater decreases in distance and near exodeviation control (MD=-1.08, 95% CI: -1.96 to -0.20, P=0.02; OR, -0.64, 95%, -1.15 to -0.13; P < 0.001). Patients who received overminus lens therapy had a greater decrease in the deviation at both distance and near (OR, -2.88; 95% CI, -3.75 to -2.01, P < 0.001; OR, -3.44; 95% CI, -5.34 to -1.55; P < 0.001). There was no statistical difference between the two groups in terms of post-treatment proximal stereopsis (OR=0.01, 95% CI: -0.04 to 0.05, P=0.83). Conclusions The present meta-analysis indicated that overminus lens therapy was effective in improving the control and decreasing exodeviation angle of intermittent exotropia. However, it seemed not to be effective in improving the level of near stereopsis.

4064 Background: Camrelizumab combined with chemotherapy has a very ideal therapeutic effect and low toxicity in the treatment of solid tumors. camrelizumab plays an important role in the treatment of locally advanced esophageal squamous cell carcinoma. Methods: This study is a prospective, multicenter, randomized controlled study. Inclusion criteria were patients aged 18-75 years with an ECOG score of 0-1 who had not received other treatments previously and had histologically confirmed resectable locally advanced esophageal squamous cell carcinoma (clinical stages cT1-4N1-3M0 and cT3-4N0M0). Patients received camrelizumab combined with chemotherapy (albumin paclitaxel + cisplatin in chemotherapy regimen) or chemotherapy alone (albumin paclitaxel + cisplatin in chemotherapy regimen). The primary endpoints are pathological complete remission (pCR) rate and 5-year overall survival (OS). Secondary endpoints including disease-free survival rate, duration of drug treatment and adverse events and we attempt to explore the correlation between drug efficacy and PD-L1 expression. The target sample size was 400 and patients were divided into two groups according to a 1:1 ratio who were received camrelizumab plus chemotherapy and chemotherapy alone. Results: From January 2021 to October 2022, 243 patients with resectable locally advanced esophageal squamous cell carcinoma from four centers were enrolled. Of these, 205 (85.2%) were male and 38 (15.6%) were female. Median age was 65 years. Most patients (182, 74.9%) were in clinical stage III and had an ECOG score of 1 (185, 76.1%). 150 patients had completed all clinical trial cycles and the result showed that among 90 patients who received camrelizumab plus chemotherapy, 25 patients achieved pathological complete remission(pCR), 39 achieved major partial remission (MPR), 11 had stable disease and 1 had progressive disease, with a pCR rate of 27.8% and MPR rate of 43.3%. Among 60 patients who received chemotherapy alone, 6 patients achieved pCR, 13 patients achieved MPR, 19 patients had stable disease and 2 patients had progressive disease, with a pCR rate of 10.0% and MPR rate of 26.7%. The most common adverse events were reactive cutaneous capillary endothelial proliferation (72.1%), nausea (42%), and leukopenia (15.5%), all of which were in grade 1 – 2 with manageable safety. Conclusions: Preliminary results of this study showed that the overall efficacy of camrelizumab plus chemotherapy was better than that of chemotherapy alone and the drug was safe and reliable. In future work, we will continue to analyze the survival outcomes, drug safety and the relationship between drug efficacy and PD-L1 expression and other biomarkers. Clinical trial information: ChiCTR2000040330 .

Objective To compare the effectiveness of part-time occlusion therapy（PTO） and observation in the treatment of intermittent exotropia(IXT). Methods An exhaustive search of the literature from Pubmed, EMBASE, Web of Science, and Cochrane Library databases was carried out until July 2022. No language restrictions were applied. The literature was rigorously screened against eligibility criteria. Weighted mean differences (WMD) and 95% confidence interval (CI) was calculated. Results A total of 4 articles with 617 participants were included in this meta-analysis. Our pooled results showed that PTO exhibited superior effects compared to observation, with greater decrease in exotropia control at distance and near (MD=-0.38, 95% CI: -0.57 to -0.20, P<0.001; MD=-0.36, 95%CI, -0.54 to -0.18, P<0.001), patients subjected to PTO therapy had greater decrease in distance deviations (MD=-1.95, 95% CI: -3.13 to -0.76, P=0.001). And there was greater improvement in near stereoacuity among PTO group in comparison with observation group (P<0.001). Conclusion The present meta-analysis indicated that part-time occlusion therapy showed a better effect in improving control and near stereopsis, and decreasing distance exodeviation angle of children with intermittent exotropia in comparison with observation.